Average Co-Inventor Count = 8.74
ph-index = 10
The patent ph-index is calculated by counting the number of publications for which an author has been cited by other authors at least that same number of times.
Company Filing History:
1. Array Biopharma Inc. (50 from 329 patents)
2. Loxo Oncology, Inc. (8 from 34 patents)
3. Eli Lilly and Company (5 from 4,449 patents)
4. Petra Pharma Corporation (3 from 4 patents)
5. Genentech, Inc. (1 from 3,224 patents)
58 patents:
1. 11998545 - Substituted pyrazolo[1,5-a]pyridine compounds as RET kinase inhibitors
2. 11970485 - RET kinase inhibitors
3. 11964968 - Compounds useful for inhibiting RET kinase
4. 11964988 - Fused heterocyclic compounds as RET kinase inhibitors
5. 11878970 - Allosteric chromenone inhibitors of phosphoinositide 3-kinase (PI3K) for the treatment of disease
6. 11873295 - Allosteric chromenone inhibitors of phosphoinositide 3-kinase (PI3K) for the treatment of disease
7. 11851434 - Substituted pyrazolo[1,5-A]pyrazine compounds as ret kinase inhibitors
8. 11807651 - Process for the preparation of 6-(2-hydroxy-2-methylpropoxy)-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile
9. 11697647 - RET kinase inhibitors
10. 11649227 - Allosteric chromenone inhibitors of phosphoinositide 3-kinase (PI3K) for the treatment of disease
11. 11648243 - Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors
12. 11613533 - Compounds useful for inhibiting RET kinase
13. 11603374 - Substituted pyrrolo[2,3-d]pyrimidines compounds as ret kinase inhibitors
14. 11524963 - Substituted pyrazolo[3,4-d]pyrimidines as RET kinase inhibitors
15. 11472802 - Substituted pyrazolyl[4,3-c]pyridine compounds as RET kinase inhibitors